Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HIMX | <0.01% | $1.65B | +18.89% | 3.20% |
CSW | <0.01% | $4.87B | +9.23% | 0.33% |
VIAV | <0.01% | $2.23B | +45.56% | 0.00% |
LKQ | -<0.01% | $9.58B | -10.75% | 3.24% |
MLCO | -0.01% | $2.96B | -3.49% | 0.00% |
MAN | -0.01% | $1.87B | -42.02% | 5.54% |
SCSC | 0.01% | $947.89M | -5.33% | 0.00% |
RDNT | 0.01% | $4.29B | -3.06% | 0.00% |
HNI | 0.02% | $2.31B | +10.22% | 2.67% |
TAL | -0.02% | $4.93B | +0.19% | 0.00% |
FLXS | 0.02% | $192.90M | +17.77% | 1.91% |
LFCR | -0.02% | $303.24M | +59.65% | 0.00% |
CRCT | 0.03% | $1.37B | +16.76% | 3.07% |
PFSI | -0.03% | $5.12B | +4.80% | 1.21% |
CPB | 0.03% | $9.18B | -31.87% | 4.94% |
GNRC | 0.04% | $8.41B | +7.71% | 0.00% |
TNK | 0.04% | $1.46B | -37.17% | 2.38% |
AUDC | -0.04% | $289.38M | -6.07% | 3.67% |
ETSY | 0.05% | $5.28B | -14.14% | 0.00% |
MAX | -0.06% | $604.23M | -17.92% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LDOS | -26.70% | $20.04B | +6.72% | 1.01% |
ZETA | -24.57% | $3.56B | -14.39% | 0.00% |
INSG | -23.79% | $128.32M | -19.79% | 0.00% |
CACI | -22.43% | $10.19B | +7.73% | 0.00% |
PLUS | -22.19% | $1.94B | -0.64% | 0.00% |
SAIC | -22.14% | $5.12B | -7.07% | 1.36% |
ICFI | -20.61% | $1.55B | -43.24% | 0.66% |
DOLE | -19.66% | $1.32B | +13.07% | 2.35% |
MMS | -19.56% | $3.94B | -18.33% | 1.72% |
BAH | -18.27% | $12.76B | -33.16% | 2.06% |
CHMI | -17.88% | $98.96M | -16.53% | 21.05% |
HALO | -17.36% | $6.43B | -0.29% | 0.00% |
DOX | -17.03% | $10.12B | +15.32% | 2.15% |
IAS | -16.02% | $1.33B | -17.28% | 0.00% |
SYM | -14.75% | $4.06B | +5.94% | 0.00% |
MLYS | -14.65% | $893.55M | +17.18% | 0.00% |
PSFE | -14.51% | $745.82M | -28.90% | 0.00% |
GTM | -14.47% | $3.32B | -20.99% | 0.00% |
PGNY | -14.25% | $1.88B | -23.42% | 0.00% |
SGRY | -14.17% | $2.81B | -7.73% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
QLTA | -<0.01% | $1.61B | 0.15% |
CGCB | 0.01% | $2.47B | 0.27% |
FLTW | 0.03% | $545.69M | 0.19% |
COPX | -0.04% | $1.83B | 0.65% |
FLCB | -0.05% | $2.59B | 0.15% |
FISR | 0.06% | $430.04M | 0.5% |
IGRO | -0.07% | $1.18B | 0.15% |
PBE | -0.07% | $223.16M | 0.58% |
EWT | -0.08% | $5.95B | 0.59% |
CQQQ | 0.10% | $1.04B | 0.65% |
BIV | 0.11% | $23.34B | 0.03% |
VGIT | -0.11% | $31.83B | 0.04% |
LQD | 0.14% | $29.42B | 0.14% |
JCPB | -0.14% | $6.83B | 0.38% |
SPTS | 0.15% | $5.78B | 0.03% |
CGCP | 0.17% | $5.18B | 0.34% |
IBB | 0.18% | $5.36B | 0.45% |
SPBO | 0.18% | $1.61B | 0.03% |
TIP | -0.18% | $14.02B | 0.18% |
EUSB | -0.18% | $732.60M | 0.12% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
HYDR | 19.51% | $32.35M | 0.5% |
MSOS | 18.29% | $302.96M | 0.77% |
ARGT | 16.26% | $1.02B | 0.59% |
AMLP | 15.88% | $10.44B | 0.85% |
CNBS | 15.78% | $54.42M | 0.77% |
MLPA | 15.72% | $1.77B | 0.45% |
VPC | 15.06% | $53.69M | 9.86% |
FAN | 15.04% | $176.15M | 0.6% |
EMLP | 14.34% | $3.26B | 0.96% |
VPU | 14.08% | $6.99B | 0.09% |
USTB | 14.04% | $1.29B | 0.35% |
MEAR | 14.00% | $1.12B | 0.25% |
QAI | 14.00% | $703.39M | 0.91% |
XLU | 13.92% | $18.86B | 0.09% |
FUTY | 13.76% | $1.81B | 0.084% |
FXU | 13.73% | $1.65B | 0.64% |
FPEI | 13.56% | $1.60B | 0.85% |
YOLO | 13.41% | $24.06M | 1.12% |
DVY | 13.27% | $19.38B | 0.38% |
BIZD | 13.27% | $1.57B | 12.86% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FXE | -12.78% | $568.58M | 0.4% |
TAIL | -11.00% | $99.76M | 0.59% |
VIXY | -10.57% | $165.69M | 0.85% |
KCCA | -10.52% | $104.88M | 0.87% |
UDN | -10.27% | $147.10M | 0.78% |
FXC | -9.24% | $92.55M | 0.4% |
IBND | -8.58% | $378.69M | 0.5% |
IHF | -8.53% | $648.78M | 0.4% |
BTAL | -8.00% | $296.79M | 1.43% |
ZROZ | -7.39% | $1.51B | 0.15% |
GOVZ | -7.34% | $270.29M | 0.1% |
BWX | -6.56% | $1.53B | 0.35% |
FXB | -6.40% | $91.76M | 0.4% |
IGOV | -5.91% | $1.20B | 0.35% |
EDV | -5.64% | $3.48B | 0.05% |
CARY | -5.62% | $347.36M | 0.8% |
BUXX | -5.47% | $318.71M | 0.25% |
DRSK | -4.93% | $1.27B | 0.78% |
TLT | -4.85% | $48.88B | 0.15% |
BAR | -4.85% | $1.12B | 0.1749% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HNST | 38.06% | $537.96M | +67.12% | 0.00% |
PAY | 33.55% | $4.04B | +69.74% | 0.00% |
DAVE | 31.04% | $3.33B | +723.89% | 0.00% |
BE | 29.75% | $5.15B | +81.21% | 0.00% |
HNRG | 27.74% | $659.25M | +97.43% | 0.00% |
ETON | 27.19% | $375.71M | +325.84% | 0.00% |
CAE | 25.75% | $9.00B | +51.13% | 0.00% |
DSP | 25.22% | $831.51M | +34.65% | 0.00% |
TGS | 25.06% | $1.90B | +43.78% | 0.00% |
FIHL | 24.97% | $1.78B | -0.25% | 1.84% |
RKLB | 24.95% | $16.33B | +637.08% | 0.00% |
GFF | 24.82% | $3.42B | +13.76% | 0.94% |
PRDO | 24.23% | $2.16B | +53.97% | 1.57% |
NTRA | 24.14% | $22.93B | +55.10% | 0.00% |
DIS | 24.10% | $219.94B | +23.21% | 1.17% |
SPOT | 23.65% | $155.23B | +146.22% | 0.00% |
TSEM | 22.56% | $4.85B | +10.48% | 0.00% |
JOYY | 21.60% | $1.81B | +69.16% | 3.66% |
TEO | 21.30% | $1.12B | +23.51% | 0.00% |
BBDC | 20.79% | - | - | 11.43% |
Yahoo
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced first quarter financial results for 2025 and provided a corporate update.
Yahoo
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2024 and provided a corporate update.
Yahoo
Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader
Current Value
$6.871 Year Return
Current Value
$6.871 Year Return